(NASDAQ: ORIC) Oric Pharmaceuticals's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.39%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Oric Pharmaceuticals's revenue in 2024 is $0.On average, 2 Wall Street analysts forecast ORIC's revenue for 2026 to be $1,383,977,696, with the lowest ORIC revenue forecast at $191,142,240, and the highest ORIC revenue forecast at $2,576,880,574. On average, 1 Wall Street analysts forecast ORIC's revenue for 2027 to be $11,113,218,863, with the lowest ORIC revenue forecast at $11,113,218,863, and the highest ORIC revenue forecast at $11,113,218,863.
In 2028, ORIC is forecast to generate $29,442,647,244 in revenue, with the lowest revenue forecast at $29,442,647,244 and the highest revenue forecast at $29,442,647,244.